It is unknown whether the glycosaminoglycan drug sulodexide interferes with transforming growth factor-b1-a member of heparin-binding family and a potent regulator of human biology and diseases. Hence, a 2-week pilot study was performed in 11 healthy men. Sulodexide was initially administered intravenously in a single dose, then-orally for 12 days and-again intravenously on study completion. Initial injection had no effect on activated form of the growth factor measured in plasma after 10 and 120 min; no change was also observed after 120 min from drug ingestion on day 7.
It is unknown whether the glycosaminoglycan drug sulodexide interferes with transforming growth factor-b1-a member of heparin-binding family and a potent regulator of human biology and diseases. Hence, a 2-week pilot study was performed in 11 healthy men. Sulodexide was initially administered intravenously in a single dose, then-orally for 12 days and-again intravenously on study completion. Initial injection had no effect on activated form of the growth factor measured in plasma after 10 and 120 min; no change was also observed after 120 min from drug ingestion on day 7.
On final intravenous administration, the growth factor levels increased by almost 60% after 10 min and remained elevated; the 120-min levels directly correlated with sulodexide dosage. Baseline cytokine levels decreased during the 2-week trial by more than 50%. In conclusion, transforming growth factor-b1 release and likely downregulation of its expression may constitute novel pharmacological effects of sulodexide.
Keywords: sulodexide; transforming growth factor-b1; glycosaminoglycan; humans S ulodexide is a purified glycosaminoglycan (GAG) medication consisting of 80% fastmoving heparin fraction (containing heparan sulfate) and 20% dermatan sulfate (also known as chondroitin sulfate-B). The drug exhibits less significant anticoagulant activity compared with that of heparin and is available in both parenteral and oral formulation. [1] [2] [3] Several trials proved that sulodexide is effective in the treatment of diabetic nephropathy and other glomerulopathies, and in the treatment and/or prevention of ischemic cardiovascular events, deep vein thrombosis, venous leg ulcers, cerebrovascular dementia, and complications of peritoneal dialysis. The drug is also protective against endothelial damage, diminishes neointimal proliferation and restenosis of injured arteries, blunts systemic and local inflammation (for review see references [3] [4] [5] [6] , and may be used in heparin-induced thrombocytopenia type II. 7 Interestingly, these beneficial effects of sulodexide may be only partially explained by its anticoagulant actions, which suggest some underrecognized mechanisms of the drug. In view of the emerging and intriguing extra-anticoagulant actions of the structurally and functionally like heparin, [8] [9] [10] it seems attractive to hypothesize that some effects of sulodexide also may be accomplished via its influence on pleiotropic growth factors.
The transforming growth factor-b1 (TGF-b1) affects crucial biological phenomena such as embryonic development, cell growth, differentiation, maturation, apoptosis, and so on. It is also strongly implicated in the development/progression of numerous human diseases, including wound healing, organ fibrosis, angiogenesis, atherosclerosis, immunoregulation, cancer, infection, and others. [11] [12] [13] [14] [15] Generally, the cytokine is regarded as a potent reparative and regenerative factor, while-when overproduced and unopposed under pathological conditions-as a prototypical and aggressive profibrotic agent. Transforming growth factor-b1 belongs to a family of heparin-binding growth factors, and its latent form shows a significant affinity for heparan sulfate-rich GAGs residing in the extracellular matrix and on virtually all mammalian cells. These GAGs, and as a result TGF-b1, are localized in abundant stores on the surface of endothelial cells and within the vascular wall, where they are readily accessible and amenable to pharmacological modification, especially by exogenous GAG-based compounds (ie, heparin). [16] [17] [18] [19] To investigate the hypothesis that intravenous (IV) and/or oral administration of heparinoid sulodexide may affect plasma TGF-b1 levels, we performed an open-label, prospective pilot trial in healthy volunteers.
Methods

Patients
Eleven male participants, aged 30.4 + 1.16 years, with a mean body weight of 84.5 + 11.1 kg, height of 1.81 + 0.05 m, and body mass index of 25.7 + 2.44 kg/m 2 were enrolled. They were healthy nonsmokers and no drug or alcohol abusers as ascertained by history, physical examination, and laboratory tests. Special attention was given to arterial blood pressure, mental disorders, history of drug hypersensitivity, bleeding and thrombotic disorders, gastroduodenal disease, complete blood counts, urinalysis, serum C-reactive protein, creatinine, liver enzymes, viral hepatitis B/C and human immunodeficiency virus infection, blood glucose, and routine hemostatic tests. None of the participants experienced major trauma, surgery, or infection in the preceding month and was not receiving any medications within the past 2 weeks.
Study Protocol
The study conformed to the Declaration of Helsinki and Good Clinical Practice guidelines, and was approved by the Ethics Committee of Medical University of Bialystok, Poland. Written informed consents were obtained from the participants.
On day 1, fasting blood samples (T 0 ) were obtained from the antecubital vein by atraumatic puncture with an 18-gauge needle without the use of tourniquet, and sulodexide (Vessel Due F; Alfa Wassermann SpA, Bologna, Italy) was injected IV at a dose of 1200 lipoprotein lipase releasing units (LRU, 2 ampoules of 2 mL-a single ampoule contains 600 LRU ¼ 60 mg). Then, the participants remained ambulatory within the clinic and were allowed habitual water intake; the consecutive blood samples were drawn after 10 (T 10 ) and 120 min (T 120 ). Next, the volunteers were asked to take oral sulodexide at a daily dose of 1000 LRU [500 LRU twice a day (bid)] for 12 consecutive days. On day 7, fasting blood samples were obtained at T 0 ; then the participants took the prescribed 500 LRU of oral sulodexide, and the sampling was repeated at T 120 . On day 14, no usual morning oral dose was administered, and 1200 LRU of the drug was again injected IV; further procedures strictly followed those performed on day 1. Then, the study was terminated.
The daily oral sulodexide dose of 1000 LRU was chosen based on those used in a majority of previous clinical trials. [3] [4] [5] [6] The IV dose of 1200 LRU was selected as a part of a phase I study. Drug compliance was evaluated by questioning the participants and counting the capsules. The study period was uneventful; no delayed adverse effects of sulodexide were revealed in the medical history and the examination performed 1 month after the study completion.
Plasma TGF-␤1 Determination
The blood samples were collected in Diatube H plasma preparation tubes (Diagnostica Stago, Plymouth, UK; containing sodium citrate, adenosine, theophylline, and dipyridamole). This specific blood collection for plasma TGF-b1 determination was used to minimize platelet degranulation and the release of the growth factor (more than 90% of the serum TGF-b1 originates from the thrombocytes). 20, 21 Plasma was prepared by immediate centrifugation at 3000g for 20 minutes at ambient temperature, aliquoted, and stored at À70 C to allow batch analysis.
To measure TGF-b1, the monoclonal antibodybased immunoenzymatic assay (ELISA) kit (Quantikine, R&D Systems, Inc, Minneapolis, Minn; cat no. DB100) was used. The assay is generally regarded as referential, 20 and its detection limit is 7 pg/mL. As a capture reagent, it uses the mammalian type II receptor (expressed by the mouse myeloma nonimmunoglobulin secreting cell line) precoated onto a microplate. To transform all latent TGF-b1 to its biologically active (free) 25 kd mature dimer, the acid and urea activation step followed by sample neutralization were performed according to the manufacturer's recommendation. All plasma samples were processed in duplicate, measured with a 400 SFC photometer (SLT-Labinstruments, Grö ding/ Salzburg, Austria), and calibrated against the provided recombinant human reference samples and standards. For calculating the results, a computer and a curve-fitting program were used. The intraand inter-plate coefficients of variations were <6%.
Statistical Analyses
All the data had skewed distribution as provided by Shapiro-Wilk W test, and they were expressed as median (minimal-maximal) values. Differences in plasma TGF-b1 levels during IV sulodexide injection on day 1 and 14, as well as between the baseline TGF-b1 concentrations on day 1, 7, and 14 (3 time points), were assessed with the nonparametric Friedman analysis of variance (ANOVA) by rank test and Kendall concordance. The TGF-b1 levels measured at 2 time points (during oral administration on day 7) were compared with Wilcoxon matched pairs test. Associations between the variables of interest were assessed with the nonlinear Spearman rank order regression analysis. The fixed dose of sulodexide administered to the patients was corrected for the body weight and regarded as the effective dose. The 2-sided P < .05 values were considered significant. Statistica 6.0 PL for Windows (StatSoft, Tulsa, Okla) data analysis package was used.
Results
Plasma TGF-b1 levels remained stable following initial IV injection of sulodexide ( 2 ANOVA ¼ 1.71, P ¼ .761) and were 1.87 (1.18-4.56) ng/mL at T 0 , 1.91 (1.24-4.30) ng/mL at T 10 , and 1.60 (0.91-5.11) ng/mL at T 120 . They did not change after oral administration of the drug on day 7, either and were 1.12 (0.74-3.54) ng/mL at T 0 and 1.13 (0.61-3.64) ng/ mL after 120 min from ingestion (P ¼ .657).
In contrast to day 1, TGF-b1 levels on day 14 significantly changed following IV sulodexide administration ( 2 ANOVA ¼ 16.5, P ¼ .0002; Figure 1A ). They increased from 1.04 (0.54-4.38) ng/mL at T 0 to 1.81 (1.19-5.85) ng/mL at T 10 (uniformly in all participants, a median rise of 57.3%, P ¼ .003) and remained elevated by a median of 29.3% at T 120 [1.65 (0.80-4.37) ng/mL, P ¼ .018 vs. baseline]. On that day, the increased T 120 TGF-b1 levels directly correlated with the IV sulodexide dose per kilogram of body weight ( ¼ .789, P ¼ .004, Figure 2A ); the relation between the percentage increment in TGF-b1 (Á TGF-b1 T 120 vs. T 0 ) and the sulodexide dose also was positive but nonsignificant ( ¼ .454, P ¼ .201). After exclusion of the single outlier receiving the highest dose of the medication (Figure 2A ), the associations were: ¼ .718, P ¼ .012 and ¼ .688, P ¼ .017, respectively. Noteworthy, the correlation between Á TGF-b1 T 120 vs. T 0 and the sulodexide dose became statistically significant ( Figure 2B ). No such phenomena were revealed for either the TGF-b1 level or its increase at T 10 (all P > .350).
Regarding the baseline TGF-b1 levels ( Figure  1B) , they changed significantly during the 2-week sulodexide trial ( 2 ANOVA ¼ 13.8, P ¼ .001). Compared with day 1, the T 0 TGF-b1 values on day 7 were lower by a median of 43.4% (P ¼ .008) and decreased in all but 1 participant. On day 14, they remained comparably decreased and were even further numerically lower (by 54.0% vs. T 0 on day 1, P ¼ .003).
Discussion
The main findings of this pilot study performed for the first time in healthy men are that the sulodexide injection may lead to a rapid and dose-dependent increase in plasma TGF-b1 concentration, and that a 2-week sulodexide ingestion results in a significant 50% fall in the circulating level of the growth factor. In view of the complex role of TGF-b1 in human biology and its peculiar and dissimilar regulatory behavior in health and disease, [11] [12] [13] [14] [15] it is vague to decipher whether the above effects of sulodexide are beneficial or not. They may constitute, however, a new mechanism of action of this heparinoid drug. It is conceivable that the release of TGF-b1 from its most active sites such as the endothelium and the extracellular matrix, along with its ongoing depletion, may compromise the important physiologic role of the growth factor in the healthy organism. [11] [12] [13] [14] [15] The continuing decrease in baseline plasma TGF-b1 concentration observed in our trial is in agreement with the experiment showing that sulodexide was capable of suppressing TGF-b1 gene overexpression within the diabetic kidneys, 22 similar to the actions of heparin in other nephropathies. [23] [24] [25] The behavior of plasma TGF-b1 following IV sulodexide administration has not been studied before. However, the growth factor level was found to increase during hemodialysis in chronic renal failure patients anticoagulated with a low-molecular-weight heparin enoxaparin for blood purification procedures. 26 Analogously to our sulodexide trial, the percentage increment in plasma TGF-b1 under enoxaparin was comparable, and its magnitude also was directly related to the anticoagulant dosage. 26 Likewise, the methods of sample obtaining and preparation, as well as the immunoassay and laboratory equipment used, were also identical in the 2 works.
Regarding putative mechanisms underlying the increase in plasma TGF-b1 level after heparin administration, a number of effects should be considered. Based on the pharmacological ''mimicry'' of sulodexide, 1-3 it seems conceivable that they also may be pertinent to this heparinoid drug. First, heparin enhances activity of numerous proteases, including plasmin and metaloproteinases-2 and -9. Consecutively, such generated plasmin can cause dissociation of the inactive complex of TGF-b1 with a2-macroglobulin circulating in plasma, whereas metaloproteinases destabilize the extracellular matrix and evoke the release of active TGF-b1 from its latent complex into circulation. 16, 20, 21, 27 Second, plasma soluble TGF-b1 may originate from platelets degranulating under influence of heparin. 20 However, in our study an optimized protocol of blood sampling and plasma preparation was used; it allows-according to Grainger et al 20 -for minimization of in vitro platelet degranulation to <0.1%. Moreover, in the previous study that showed an enoxaparin-induced increase in plasma TGF-b1 when using the recommended laboratory procedures, no associations between plasma levels of the growth factor and those of b-thromboglobulin and platelet factor-4 (thrombocyte release markers) were found. 26 Thus, platelet destruction is an unlikely reason for the increase in plasma TGF-b1 observed also in the present study. The third, so far best studied, and most appreciated mechanism is a competitive release of TGF-b1 by heparin (both exogenous and originating from degranulating mastocytes) from its cell-surface (ie, endothelium) and extracellular matrix-associated heparan sulfate proteoglycans (HSPGs) stores. 9, [16] [17] [18] [19] [20] [21] This growth factor is known to remain associated with HSPGs by 2 distinct mechanisms: by direct interaction with core proteins such as decorin and betaglycan, as well as with collagen IV, fibronectin, and thrombospondin, and via a 60 kd protein. These TGF-b1 stores are readily available, amenable to pharmacological interventions, and heparin can effectively release the growth factor by a competition, resulting in its increase in circulating blood. 9, [16] [17] [18] [19] [20] [21] The multiple mechanisms outlined above are by no means mutually exclusive; all are likely to contribute to TGF-b1 augmentation by heparin and, plausibly, also by sulodexide. One of the limitations of our pilot study is the method of TGF-b1measurement that does not allow the discrimination of the latent and active (free) form of circulating TGF-b1. Therefore, we use the term ''release,'' which involves the dissociation of growth factor from its binding sites and formation of its soluble pool. We are also unable to explain why the release of TGF-b1 by IV sulodexide occurred after pretreatment with oral drug, whereas it was not observed on initial exposure. Hypothetically, the phenomenon may illustrate the equilibrium between circulating and tissue-bound pool of the factor (which has changed over the trial), as well as ongoing adaptation to the drug and/or its evolving tissue affinity. It is also hazardous to discuss possible clinical relevance of our findings, because in human diseases both increased (ie, fibrosis, advanced neoplasm) and decreased (ie, atherosclerosis, carcinogenesis, developmental defects) plasma TGF-b1 levels were observed and believed to be causative, accelerative, protective, or of unknown significance. [11] [12] [13] [14] [15] Therefore, the herein reported downregulation of TGF-b1 under oral sulodexide administration along with the growth factor release from tissues by the IV drug in a healthy organism is of apparently disputable clinical value.
Our hypothesis-generating findings need confirmation, and more studies are needed before considering that the various established therapeutic effects of sulodexide [3] [4] [5] [6] are (at least partially) exerted via its influence on the complex network of pleiotropic growth factors. In support of this pharmacologically attractive hypothesis is the fact that in vitro sulodexide also potentiated the mitogenic activity of fibroblast growth factors 1-2 and exerted stabilizing and protective effects on the factors. 28 Furthermore, our recent study showed a marked upregulation of multipotential hepatocyte growth factor under sulodexide administration in men. 29 In conclusion, sulodexide-generally considered as only supportive heparinoid drug-also influences the pleiotropic TGF-b1 system in healthy humans. This novel pharmacological effect of sulodexide may have important biological implications and deserves further investigations, particularly in fibrotic diseases.
